Navigation Links
S*BIO's JAK2 Inhibitor SB1518 Granted Orphan Drug Designation by European Commission (EC) for the Treatment of Myelofibrosis (MF)
Date:10/18/2010

s grants potential market exclusivity of up to 10 years in the EU.

MF is a serious progressive and chronic condition, whereby scar tissue develops in the bone marrow, resulting in a reduced ability to produce sufficient blood cells. Consequently, more blood cells are made in other organs, such as the liver and spleen, which are not as efficient at blood cell production as the bone marrow.  MF is characterized by an enlarged spleen and progressive anaemia.  Current therapies for MF are mostly palliative in nature and survival rates can be short.  While the actual cause of the disease is unknown, the JAK2 gene has been implicated in the development of this condition.

About S*BIO Pte LtdS*BIO is a privately-held biotech company focused on the research and clinical development of novel targeted small molecule drugs for the treatment of cancer with leading programs around histone deacetylases (HDAC) and kinases. S*BIO's lead candidate, SB939, entered the clinic in 2007. SB1518, S*BIO's potent and orally-active JAK2 inhibitor, entered the clinic in 2008 and has received orphan drug designation from the U.S. FDA. S*BIO has entered into a development collaboration, and option & license agreement with Onyx Pharmaceuticals, Inc. to develop and commercialize SB1518 and its other novel JAK2 inhibitor, SB1578 in North America and Europe. S*BIO's SB1317, a novel multikinase inhibitor, is in preclinical development and under a worldwide exclusive license with Tragara Pharmaceuticals, Inc. for its development and commercialization.

In line with its vision to be a leading fully-integrated oncology-focused biotech company in Asia Pacific, S*BIO has established a state-of-the-art R&D infrastructure, complemented by a strong clinical development team. S*BIO has strong links with a network of medical oncologists in Asia Pacific and its investors include Bio*One Capital a subsidiary of EDBI (EDB Investments), Aravis Ventures, Mitsui Ventures
'/>"/>

SOURCE S*BIO
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. For the Treatment of Rheumatoid Arthritis, Surveyed European Rheumatologists Expect Well-Established TNF-Alpha Inhibitors to Lose Considerable Patient Share to Newer Agents in This Drug Class
2. For Multiple Myeloma Treatment, More Surveyed European Clinicians Consider the Combination of Immunomodulatory Agents and Proteasome Inhibitors Promising With Respect to Efficacy Than Any Other Drug Regimen Combinations
3. N30 Pharma Initiates Phase 1 Trials of Novel Reductase Inhibitor
4. ViroPharma Announces Publication of Cinryze™ (C1 Esterase Inhibitor [Human]) Phase 3 Trial Results in Hereditary Angioedema (HAE) in the New England Journal of Medicine
5. ViroPharma Files Prior Approval Supplement (PAS) for Cinryze™ (C1 Esterase Inhibitor [Human]) Industrial Scale Manufacturing
6. FDA: Possible Fracture Risk With High Dose, Long-term Use of Proton Pump Inhibitors
7. Proton Pump Inhibitor DEXILANT(TM) (dexlansoprazole) Now Available in U.S. Pharmacies
8. Portola Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of PRT062607, an Oral, Syk-Specific Inhibitor for Chronic Inflammatory Disease Indications
9. Genomic Health Announces Publication of Study Using Oncotype DX(R) in Node-Negative and Node-Positive Breast Cancer Patients Treated With Aromatase Inhibitors
10. Takeda Announces Initiation of Trial to Study the Concomitant Use of Dexlansoprazole and Other Proton Pump Inhibitors with Plavix(R) (clopidogrel bisulfate)
11. Neurocrine Advances VMAT2 Inhibitor Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... June 1, 2015 NSHOA Cancer Center ... today announced positive, top-line results from its recently ... efficacy and safety of the Company,s 5-HT 3 ... (granisetron injection, extended release) as part of a ... 1 ) receptor antagonist fosaprepitant and the IV ...
(Date:6/1/2015)... , June 1, 2015 Researchers from ... Case Western Reserve University School of Medicine will present ... a potential novel combination treatment for cancer patients with ... mutations in small cell lung cancer (SCLC), at the ... Annual Meeting in Chicago . ...
(Date:6/1/2015)... 1, 2015   OTC Markets Group Inc. ... Connected financial marketplaces for 10,000 U.S. and global ... San Diego -based biopharmaceutical company, on its ... only public venture market for entrepreneurial and development ... "We,re happy to congratulate ...
Breaking Medicine Technology:New cancer therapy study results - MAGIC Trial 2UH Case Medical Center Experts to Present Data at 51st ASCO Annual Meeting 2UH Case Medical Center Experts to Present Data at 51st ASCO Annual Meeting 3OTC Markets Group Congratulates OncoSec Medical on NASDAQ Listing 2
(Date:6/2/2015)... FDA approved Orlistat for weight loss ... satisfactory doctor consultation. The less potent, over-the-counter version of Orlistat, ... has the longest track record as an FDA approved weight ... down fats in foods, Orlistat treatment prevents the body from ... be excreted through feces. , The most common ...
(Date:6/2/2015)... (PRWEB) June 02, 2015 Thermi, ... technology company has successfully transitioned into its new ... due to the company’s continued rapid worldwide expansion ... comprised of over 25 Thermi employees, including those ... development teams. , “As one of the fastest ...
(Date:6/2/2015)... (PRWEB) June 02, 2015 While the ... adaptions of comic books, comic books themselves are stepping ... Comics Uniting Nations plans to produce educational comics in ... Global Goals for Sustainable Development - an international effort ... poverty, hunger, health, education, sustainable energy, inequality, climate change ...
(Date:6/2/2015)... SB 277 (CA Legislature, bit.ly/1Q0P8OY) will require ... public or private school. SB277 cleared three Senate policy ... Committee (Sacramento Bee, May 11, 2015, bit.ly/1Gh9jU7). It passed ... “We believe that this bill affects the education of ... will (the) affect public health of California.. It is ...
(Date:6/2/2015)... “We want men to realize the importance of protecting ... Phillips, owner of SunGrubbies.com, “that is why we offer ... that work well for outdoor activities.” , The effects of ... can take up to thirty years to develop. The ... cancer to occur. That is why the simple act ...
Breaking Medicine News(10 mins):Health News:Diet Doc Adds FDA Approved Orlistat to their Medically Supervised Diet Plans, Offering Their Patients another Option for Trimming Fat from the Hard to Reach Areas 2Health News:Diet Doc Adds FDA Approved Orlistat to their Medically Supervised Diet Plans, Offering Their Patients another Option for Trimming Fat from the Hard to Reach Areas 3Health News:Diet Doc Adds FDA Approved Orlistat to their Medically Supervised Diet Plans, Offering Their Patients another Option for Trimming Fat from the Hard to Reach Areas 4Health News:Thermi Moves to New Corporate Headquarters as Rapid Company Expansion Continues 2Health News:Can Comics Help the United Nations Save the World? 2Health News:Can Comics Help the United Nations Save the World? 3Health News:A Voice For Choice Releases A Statement As SB277 Is Referred To Single Assembly Committee And Bypasses Education and Judicial Scrutiny 2Health News:It is Time to Show Father Who Knows Best, Says SunGrubbies.com, a Leading Online Sun Protection Retailer 2
... Md., Aug. 12 The third annual Psoriasis Cure Now ... a theme of helping psoriasis patients connect with one another. ... patients to resist the social isolation that often results from ... with psoriasis and psoriatic arthritis to provide mutual support and ...
... French . , Montreal, August 12, 2009 Sounds ... according to a new Canadian study. In the online edition of ... PNAS ), scientists from the Universit de Montral and the Montreal ... in the brain allows people to distinguish between different types of ...
... ... of device, new trials , ... San Diego, CA (PRWEB) August 12, 2009 -- OcumatRx, an early stage ... permanent treatment of patients with Glaucoma, has announced the successful completion of clinical trials ...
... , , Milestone shows ... shows how much the culture has changed when reporting medical events , ... Safety Authority has collected over one million reports from Pennsylvania healthcare facilities ... events that did not cause harm to the patient. , , ...
... Hard to Treat Diseases (HTDS.PK) www.htdsmedical.com - ... 2009 http://www.pinksheets.com/pink/quote/quote.jsp?symbol=htds today at 10:30AM EST that ... correct the ownership of its intellectual property (IP) rights. ... five (5) issued patents, HTDS finds that the Company ...
... ROCHESTER, N.Y., Aug. 12 VirtualScopics, Inc. (Nasdaq: VSCP ... financial results for the quarter and six months ended June 30, 2009. ... Revenues for the second quarter of 2009 increased 47% to $2.5 million, compared ... Gross profit for the second quarter of 2009 increased 96% to $1.4 ...
Cached Medicine News:Health News:Psoriasis Video Contest Launched to Encourage Psoriasis Patients to Connect and Collaborate 2Health News:Human mind: Sound and vision wired through same 'black box' 2Health News:OcumatRx Announces Promising Clinical Trial Results for Implant with Potential to Permanently Treat Glaucoma 2Health News:OcumatRx Announces Promising Clinical Trial Results for Implant with Potential to Permanently Treat Glaucoma 3Health News:Pennsylvania Patient Safety Authority Marks Milestone With One Million Reports 2Health News:Pennsylvania Patient Safety Authority Marks Milestone With One Million Reports 3Health News:Pennsylvania Patient Safety Authority Marks Milestone With One Million Reports 4Health News:Hard To Treat Diseases (HTDS.PK) Completes IP Ownership Filings With U.S. Patent and Trademark Office 2Health News:Hard To Treat Diseases (HTDS.PK) Completes IP Ownership Filings With U.S. Patent and Trademark Office 3Health News:Hard To Treat Diseases (HTDS.PK) Completes IP Ownership Filings With U.S. Patent and Trademark Office 4Health News:VirtualScopics, Inc. Reports a Record Breaking Quarter 2Health News:VirtualScopics, Inc. Reports a Record Breaking Quarter 3Health News:VirtualScopics, Inc. Reports a Record Breaking Quarter 4Health News:VirtualScopics, Inc. Reports a Record Breaking Quarter 5Health News:VirtualScopics, Inc. Reports a Record Breaking Quarter 6Health News:VirtualScopics, Inc. Reports a Record Breaking Quarter 7Health News:VirtualScopics, Inc. Reports a Record Breaking Quarter 8Health News:VirtualScopics, Inc. Reports a Record Breaking Quarter 9
... of the Criterion precast gel system, allows you ... a single run. Criterion gels are wider and ... mini gel. They accommodate Bio-Rad's 11 cm ReadyStrip ... of separation and speed in 2-D electrophoretic applications. ...
... Mini-Vertical Gel System simplifies the process of separating ... It is able to run four gels at ... maximize utility and throughput, the 120 mini-vertical runs ... (W x L) at one time. The 120 ...
... High-Throughput (HTP) Protein Electrophoresis ... integrated pre-cast gel system ... protein analysis. It consists ... E-Base™ integrated power device, ...
... agarose gel electrophoresis into an automated, high-throughput ... bufferless, pre-cast system is ideal for analyzing ... and more. Fully automated, robot-compatible, and ready ... system makes your high-throughput screening assignments as ...
Medicine Products: